Cisen Pharmaceutical Co., Ltd. (SHA:603367)

Market Cap	7.40B +21.6%
Revenue (ttm)	3.44B -13.5%
Net Income	421.25M -17.2%
EPS	0.93 -17.0%
Shares Out	452.75M
PE Ratio	17.58
Forward PE	n/a
Dividend	0.38 (2.30%)
Ex-Dividend Date	Oct 13, 2025

Volume	14,492,146
Average Volume	8,493,904
Open	16.21
Previous Close	16.35
Day's Range	15.76 - 16.53
52-Week Range	12.86 - 35.20
Beta	0.33
RSI	44.92
Earnings Date	Apr 3, 2026

About Cisen Pharmaceutical

Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products in China and internationally. The company’s chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, narcotic analgesics, obstetrics and gynecology medication, digestive system medication, respiratory system medication, immune system drugs...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 3,302
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603367

Financial Performance

In 2025, Cisen Pharmaceutical's revenue was 3.44 billion, a decrease of -13.48% compared to the previous year's 3.98 billion. Earnings were 421.25 million, a decrease of -17.22%.